All News
Health inequities in rheumatology: A central theme
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.
Read Article
Secukinumab promise in PMR is real
Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.
Read Article
Closing the care divide in #JIA treatment plenary session
Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1
Biologics have changed the game!
@RheumNow https://t.co/qDqbz8JApe
Bella Mehta bella_mehta ( View Tweet)
#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed:
-SJC = good specificity. Correlated with US synovitis but not patient-defined response
-New tool, LAMDA correlated with US & patient response. May be used in RCT @RheumNow https://t.co/srVLKw2pcL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Young Patients’ AREA empowers teens/young adults w/ autoimmune disease to shape research. US-based, youth-led & grounded in empowerment, they co-design studies, train peers & advise researchers. A truly positive and meaningful initiative esp for PPIE
@RheumNow #EULAR2025 #OP0008
Mrinalini Dey DrMiniDey ( View Tweet)
❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis?
🅰️ Yes
🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025
OP0089
@RheumNow
#Strategy https://t.co/24e7wUV2FB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Can RA be intercepted?
In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles.
Abstract#OP0004
@RheumNow #EULAR2025 https://t.co/N7YwtYod8w
Jiha Lee JihaRheum ( View Tweet)
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?
Leiden post-hoc trial: these patients don’t do worse than those who never get off drug.
Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1
David Liew drdavidliew ( View Tweet)
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow #EULAR2025 #OP0033 https://t.co/KkF9xFY4Cn
Mrinalini Dey DrMiniDey ( View Tweet)
Access inequity across Europe is real.
New #RheumaFacts data show major gaps in RMD care:
🔹 Full tsDMARD access in just 4% of countries
🔹 Self-referral possible in 57%
🔹 Rheum physio reimbursed in 63%
🔹 Psych care? Only 30%.
Abstract#OP0025
@RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not absenteeism. Data from 9-country study provide further evidence that mental health is key to supporting work outcomes in RA, PsA & axSpA.
@RheumNow #EULAR2025 #OP0028
Mrinalini Dey DrMiniDey ( View Tweet)
STAMP RCT early SEC vs. SoC 120pts
Retention 58% vs 30%
ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6
Dactylitis no difference
Of note here SoC was a tight T2T strategy!
@RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2025 Abstr#OP0075 Interesting that even among #SLE patients, no single definition of “Lupus Under Control” reached at least 50% agreement. Live Poll with clinicians in the room further highlighted the discordant. More works are needed - to help tailor management @RheumNow https://t.co/WzkQkMD23i
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How to patients with rheumatic diseases consume online health information?
78% used internet for health information
50% use it atleast a month
66% found online information superior
41% used social media!
80% using it to find treatment optio ns!
@rheumnow #EULAR2025 https://t.co/diMCloFFVF
Links:
Bella Mehta bella_mehta ( View Tweet)
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/vqZajY0nUp
David Liew drdavidliew ( View Tweet)
Platelet rich plasma in knee #OA! They asked this to #ChatGPT ...
Whatever is out there on the internet will contaminate responses which pts rely on..:(
@rheumnow #EULAR2025 https://t.co/stlbhHp3zp
Links:
Bella Mehta bella_mehta ( View Tweet)
#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources,
#Easylupus is condensed, even more easy to read
It's better to ask your patients to use it as a reliable source!
#EULAR2025 @RheumNow https://t.co/FbYYm1dB8E
Links:
Bella Mehta bella_mehta ( View Tweet)
Debuting Fishbowl sessions at #EULAR2025 🔄💊
Lively audience engaging session in A1 on how drug prices influence treatment decisions; real-world tensions between cost, access, & physician autonomy. Transparent, interactive, and packed!
@RheumNow | Location: A1 | #EULAR2025 https://t.co/jVbviLuTZK
Jiha Lee JihaRheum ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
#MTX in new #PMR?!
RCT of #MTX was negative in early #PMR - no effect on #steroid #tapering
ACR24 #1697
At #EULAR2025
👇
+RCT of #methotrexate in PMR <8wks #steroids #Rx MTX 25 mg/wk v #placebo
N=64
⬆️GC remission ✅80% v 46%
⬇️relapse w MTX
🤔
Abst0064 @RheumNow #EULAR2025
Janet Pope Janetbirdope ( View Tweet)
